BullFrog AI Secures $7.7M in Equity Financing, Regains Nasdaq Equity Compliance, Extends Cash Runway

summarizeSummary

BullFrog AI raised $7.7 million in equity, significantly boosting its cash and stockholders' equity to regain Nasdaq compliance on one front, though it still faces a bid price delisting threat and ongoing losses.

check_boxKey Events

• Significant Equity Capital Raise

  The company raised approximately $1.9 million through its ATM program and $5.8 million through its ELOC facility (with $3.3 million received post-quarter end), totaling $7.7 million in new equity financing.

• Nasdaq Stockholders' Equity Compliance Regained

  BullFrog AI successfully increased its stockholders' equity to $4.89 million, exceeding the $2.5 million Nasdaq minimum, and received notice on April 21, 2026, that it had regained compliance with this listing rule.

• Extended Cash Runway

  The cash balance increased from $2.18 million at December 31, 2025, to $5.08 million at March 31, 2026, with management expecting current cash to fund operations for at least a year, despite an ongoing 'going concern' warning.

• Ongoing Nasdaq Bid Price Non-Compliance

  The company remains non-compliant with Nasdaq's $1.00 minimum bid price requirement, with a deadline of August 10, 2026, to regain compliance. A reverse stock split is being considered as an option.

auto_awesomeAnalysis

This quarterly report reveals BullFrog AI successfully raised approximately $7.7 million through its At-The-Market (ATM) program and Equity Line of Credit (ELOC) facility in Q1 2026 and early Q2. This substantial capital injection, representing over 67% of the company's market capitalization, was critical in increasing stockholders' equity from $2.14 million to $4.89 million, allowing the company to regain compliance with Nasdaq's minimum stockholders' equity rule. While highly dilutive, this financing has extended the company's cash runway and addressed a significant delisting threat. However, the company still faces non-compliance with Nasdaq's minimum bid price requirement and is considering a reverse stock split. The net loss for the quarter improved, and a new feasibility agreement with a global pharmaceutical company was noted, though it has not yet generated revenue.